INmune Bio Inc Total Assets
INmune Bio Inc total assets. Based on the latest financial reports, INmune Bio Inc (INMB) holds total assets worth $26.84 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INMB company net worth for the company's overall valuation and market capitalisation.
Total Assets of INmune Bio Inc (2015–2025)
Total assets of INmune Bio Inc from 2015 to 2025. This chart illustrates how INmune Bio Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for INmune Bio Inc for real-time trading data and today's change.
INmune Bio Inc - Asset Composition Analysis
INmune Bio Inc Total Assets Breakdown (December 2025)
INmune Bio Inc total assets breakdown as of December 2025. INmune Bio Inc's total assets of $26.84 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.5% |
| Accounts Receivable | $4.54 Million | 14.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how INmune Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore INmune Bio Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INmune Bio Inc's current assets represent 92.4% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 76.5% of total assets in 2025, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 14.0% of total assets.
INmune Bio Inc Competitors by Total Assets
Key competitors of INmune Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
INmune Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.04 | 4.20 | 18.90 |
| Quick Ratio | 4.04 | 4.20 | 18.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.91 Million | $27.45 Million | $86.12 Million |
INmune Bio Inc - Advanced Valuation Insights
This section examines the relationship between INmune Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 1.13 |
| Asset Growth Rate (YoY) | -18.2% |
| Total Assets | $32.35 Million |
| Market Capitalization | $36.64 Million USD |
Valuation Analysis
Above Book Valuation: The market values INmune Bio Inc's assets above their book value (1.13x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: INmune Bio Inc's assets decreased by 18.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for INmune Bio Inc (2015–2025)
The table below shows the annual total assets of INmune Bio Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $32.35 Million | -18.23% |
| 2024-12-31 | $39.56 Million | -30.59% |
| 2023-12-31 | $57.00 Million | -30.31% |
| 2022-12-31 | $81.80 Million | -18.16% |
| 2021-12-31 | $99.94 Million | +145.83% |
| 2020-12-31 | $40.66 Million | +66.14% |
| 2019-12-31 | $24.47 Million | +40.93% |
| 2018-12-31 | $17.36 Million | -5.70% |
| 2017-12-31 | $18.41 Million | +3977.32% |
| 2016-12-31 | $451.61K | +3700.77% |
| 2015-12-31 | $11.88K | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more